Hepatitis C - Complete Guide to Clinical Trials

Hepatitis C Articles

Online Guide to Clinical Trials for Viral Hepatitis in the USA Impact of Disease Severity on HCV Treatment Outcomes in HALT-C Trial 12/08/06 Factors Influencing Treatment Response in WIN-R Trial- 6/02/06 Differences in Outcomes of Treatment with PegIntron Plus Fixed-dose or Weight-based Ribavirin Based on Genotype and Viral Load in HCV Genotypes 2 and 3 in The WIN-R Trial - 5/23/06 The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients with Hepatitis C: Results from the Win-R Trial - 5/23/06 Clinical Trials Information for HCV: Clinical Trials.gov Understanding "Clinical Trials"


Online Guide to Clinical Trials for Viral Hepatitis in the USA
Alabama Mobile; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Mobile; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Arizona Scottsdale; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Scottsdale; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. California La Jolla; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin La Jolla; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Loma Linda; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Loma Linda; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Los Angeles; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Los Angeles; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Los Angeles; UCLA Medical Center Research study for subjects co-infected with Human Immunodeficiency Virus-1 (HIV-1) and hepatitis C (HCV) who are currently on stable antiretroviral therapy. Pasadena; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Pasadena; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. San Diego; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin San Diego; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. San Diego; SC Liver Research Consortium A Clinical Research Study to Test the Safety and Effectiveness of Pegylated Interferon in Combination with Thymosin in Non-Cirrhotic Adults with Chronic Hepatitis C Who Have Not Responded to IFN or IFN/Ribavirin Therapy. San Diego; SC Liver Research Consortium A Clinical Research Study to Test the Safety and Effectiveness of Pegylated Interferon in Combination with Thymosin in Chronic Hepatitis C Adults with Compensated Cirrhosis Who Have Not Responded to IFN or IFN/Ribavirin Therapy. San Francisco; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. San Francisco; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Colorado Golden; Rocky Mountain Clinical Research, Inc. Adults with Chronic Hepatitis C who previously failed FDA approved treatment: An 8-week, randomized, double blind, placebo-controlled, multicenter, study of efficacy and tolerability, safety and pharmacokinetcs using an oral research medication. Florida Gainesville; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Gainesville; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Jacksonville; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Jacksonville; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Miami; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Miami; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Miami; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Orlando; Orlando Clinical Research Center You may qualify to participate in a clinical research study of a 9-week evaluation of hepatitis C patients using the combination of ribavirin and peg-interferon alfa-2a. Georgia Atlanta; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Atlanta; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Savannah; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Savannah; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Idaho Boise; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Boise; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Illinois Chicago; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Chicago; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Iowa Iowa City; University of Iowa A study to find out how well the study drug works compared to another drug in treating chronic hepatitis B in patients with decompensated liver disease Iowa City; University of Iowa A study to evaluate the safety and antiviral activity of a new combination of drugs to treat hepatitis B Kentucky Lexington; University of Kentucky Chandler Medical Center Alcohol-induced hepatic P450s in HCV/HIV oxidative metabolism Louisville; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Louisville; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Louisville; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Louisiana New Orleans; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. New Orleans; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Maryland Baltimore; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Baltimore; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Chevy Chase; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Chevy Chase; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Chevy Chase; Chevy Chase Clinical Research/Metropolitan Gastroenterology Group Research trial for patients with Hepatitis C who have not responded to previous therapy. Massachusetts Boston; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Boston; The Liver Center, Beth Israel Deaconess Medical Center Addition of ISIS 14803 to peginterferon alfa 2b and ribavirin therapy for chronic hepatitis C patients failing to achieve a 100-fold or greater virus reduction at the 12th week of their treatment with peginterferon alfa 2b and ribavirin. Worcester; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Worcester; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Worcester; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Michigan Detroit; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Detroit; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Jackson; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Jackson; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Royal Oak; William Beaumont Hospital Addition of ISIS 14803 to peginterferon alfa 2b and ribavirin therapy for chronic hepatitis C patients failing to achieve a 100-fold or greater virus reduction at the 12th week of their treatment with peginterferon alfa 2b and ribavirin. Missouri Kansas City; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Kansas City; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin St. Louis; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. St. Louis; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin New York Bronx; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Bronx; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Bronx; Biomedical Research Alliance of New York Hepatitis C- Severe Liver Fibrosis or Compensated Cirrhosis Manhasset; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Manhasset; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Manhasset; Biomedical Research Alliance of New York Chronic Hepatitis C- Genotype 2 or 3 virus infection New York; Biomedical Research Alliance of New York Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment New York; Biomedical Research Alliance of New York Chronic Hepatitis C-Non-Responsive to Interferon Alfa Treatment New York; Biomedical Research Alliance of New York Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment New York; Biomedical Research Alliance of New York Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment New York; Biomedical Research Alliance of New York Chronic Hepatitis C-Non-Responsive to Interferon Alfa Treatment New York; Biomedical Research Alliance of New York Chronic Hepatitis C- Non-Responsive to Interferon Alfa Treatment New York; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. New York; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin New York; Columbia-Presbyterian Medical Center A Phase II/III, Randomized, Double-Blind Study of the Safety and Antiviral Activity of Ribavirin with Interferon Alpha-2b Compared to Interferon Alpha-2b Alone for the Treatment of Patients with Hepatitis C and Co-Infected with HIV New York; Columbia-Presbyterian Medical Center Assessment of the Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Combined Ribavirin and Intron®A in Pediatric Patients with Chronic Hepatitis C New York; Columbia-Presbyterian Medical Center A Phase III, Randomized, Multicenter, Efficacy and Safety Study Comparing the Combination of Pegylated-Interferon Alpha-2a and Ribavirin to REBETRON in the Treatment of Patients with Chronic Hepatitis C Infection New York; Columbia-Presbyterian Medical Center A Pilot Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of the Safety and Antiviral Activity of Oral BMS-200475 in Adults Chronically Infected With Hepatitis B Virus New York; Columbia-Presbyterian Medical Center A Double-Blind, Randomized, Placebo-Controlled Study of Adefovir Dipivoxil for the Treatment of Patients with HBeAg+ Chronic Hepatitis B Virus Infection New York; Columbia-Presbyterian Medical Center Daily versus Thrice Weekly Interferon in Combination with Ribavirin for Patients with Chronic Hepatitis C Infection who have Relapsed or Failed Prior Interferon Monotherapy New York; Columbia-Presbyterian Medical Center Daily versus Thrice Weekly Interferon in Combination with Ribavirin for Patients with Chronic Hepatitis C Infection who have not been previously treated (naïve) New York; Columbia-Presbyterian Medical Center Daily Interferon in Combination with Ribavirin for Patients with Chronic Hepatitis C Infection who have Relapsed or Failed Prior Interferon and Ribavirin Combination Therapy New York; Columbia-Presbyterian Medical Center A Randomized, Open Label, Multicenter, Efficacy And Safety Study Of Pegasys Plus Ribavirin, Pegasys Plus Cellcept, Pegasys Plus Amantadine, Or Pegasys Plus Amantadine Plus Ribavirin In Patients With Chronic HCV Infection Who Relapsed On Rebetron Therapy. New York; Columbia-Presbyterian Medical Center Efficacy of Combination Interferon Alfa -2b Plus Ribavirin (Rebetron®) for the Treatment of Previously Untreated Patients with Hepatitis C and Normal Liver Enzymes New York; Columbia-Presbyterian Medical Center An Open-Label, Fixed Dose Study To Assess The Efficacy, Safety And Tolerability Of The Combination Of Intron A Plus Ribavirin In Pediatric Subjects With Chronic Hepatitis C. New York; Biomedical Research Alliance of New York Hepatits C- Severe Liver Fibrosis New York; Biomedical Research Alliance of New York Hepatitis C- Severe Liver Fibrosis or Compensated Cirrhosis North Carolina Charlotte; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Charlotte; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Durham; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Durham; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Ohio Cincinnati; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Cincinnati; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Cleveland; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Cleveland; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Oregon Portland; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Portland; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Pennsylvania Philadelphia; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Philadelphia; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Rhode Island North Providence; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin North Providence; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. South Carolina Charleston; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Charleston; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Tennessee Memphis; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Memphis; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Texas Austin; Radiant Research - Austin, North Hepatitis C Dallas; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Dallas; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Houston; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Houston; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Virginia Fairfax; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Fairfax; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Falls Church; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Falls Church; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Richmond; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Richmond; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Washington Tacoma; Northwest Medical Specialties Phase II research study for patients with chronic Hepatitis C infection who have previously been treated for at least 3 months with any peg-interferon or interferon therapy and either did not respond, relapsed or could not tolerate the interferon. Tacoma; Northwest Kinetics Research study for people with Hepatitis C Tacoma; Northwest Kinetics Research Study for people with Chronic Hepatitis B Washington, DC Washington; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Washington; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Wisconsin Milwaukee; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Milwaukee; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. International Ponce, Puerto Rico; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Ponce, Puerto Rico; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin. Santruce, Puerto Rico; Research Site Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Santruce, Puerto Rico; Research Site Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin.

Understanding "Clinical Trials"
Ever wonder how prescription drugs come into existence? The process of inventing, testing, and then getting a drug to your neighborhood pharmacy is a monumental task. In most cases, the timeline from test tube to medicine cabinet takes a decade or more. Unfortunately, many patients need drugs before they become commercially available. There are ways to access experimental drugs while they are still in testing. The first step in navigating through the complicated world of experimental drugs is learning about "clinical trials." The following is a quick primer on clinical trials. First, you need to understand that all pharmaceutical companies must following strict rules mandated by the US Food and Drug Administration (FDA) prior to marketing approval All new drugs must go through several phases of testing before being approved by the FDA as prescription drugs. Even after approval, there's an additional phase of testing (Phase IV). After a chemical compound is identified-and believed to have some benefit for the treatment of a medical condition-a pharmaceutical company must determine how the drug works in humans. When drugs are tested in humans, it's called a "clinical trial." There are four "phases" of clinical trials. Phase I is when a drug is examined for safety in a small number of volunteers. Many drugs never move beyond this phase because, while they may work, they may also cause serious toxicities. A drug that passes a phase I clinical trial will progress to phase II in order to determine the correct dosage and potential side effects. Drugs in phase III are being studied in larger numbers of people to see if they actually work against a medical condition. Finally, if a drug is approved by the FDA, phase IV studies ensure that there are no bad long-term adverse side effects. Many people choose to enroll in a clinical trial because they need certain drugs that are not yet available. Some join clinical trials to help scientists make progress against a particular disease. Still others enter because they don't have health insurance and a clinical trial is one way to get free medical care. Whatever the reason for joining a clinical trial, it's important that patients understand the possible consequences, as well as the benefits. A drug being tested in a clinical trial may not work, it may produce bad side effects, and it's possible that it may permanently damage your body. However, there is also the possibility that the drug will work well. The following is a list of clinical trials for drugs intended to treat hepatitis B, hepatitis C, and certain forms of liver cancer. To find out if you qualify for a particular trial, you'll need to call the company for the specific trial entry criteria. Keep in mind that a clinical trial may not be conducted near you. Unless you can travel to where the trial is being held, it may not be right for you. Finally, clinical trials are constantly changing. Trials often "close" because they quickly become filled with the maximum number of patients allowed (or other reasons). Others trials "open" as pharmaceutical companies "recruit" patients to study new drugs. We'll be updating this clinical trial section periodically.

HIV AND AIDS | HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH | TESTS |
INTERNET CONFERENCE REPORTS | LINKS | ABOUT US | CONTACT US